The Significance of Model-Based Strategies in Drug Development throughout the Lifecycle and Regulatory...

Area of Science:

• Pharmacometrics and Systems Pharmacology
• Drug Development and Regulatory Science
• Biopharmaceutical Sciences

Background:

• Model-informed drug development (MIDD) is a regulatory-endorsed strategy promoted by the U.S. Food and Drug Administration (FDA).
• It integrates quantitative modeling and simulation to support decision-making throughout the drug lifecycle, including drugs, generics, and biologics.

Purpose of the Study:

• To highlight the diverse applications and benefits of MIDD in optimizing drug development processes.
• To explore the future perspectives of MIDD, particularly in emerging therapeutic areas and advanced trial designs.

Main Methods:

• Evaluation of current MIDD applications in new drug development, generic drug approval, and biopharmaceutics.
• Emphasis on computational modeling, dose optimization, clinical trial refinement, and lifecycle management strategies.

Main Results:

• MIDD significantly optimizes dose selection, refines clinical trial design, and addresses regulatory concerns for efficacy and safety.
• Computational modeling in biopharmaceutics guides formulation development and in vivo studies.
• Mathematical modeling facilitates efficient development and approval of complex generic formulations, reducing time and cost.

Conclusions:

• MIDD is a transformative approach providing robust tools for decision-making and regulatory assessment in drug development.
• Its application is expected to enhance innovation, improve patient outcomes, and reduce development costs across various therapeutic domains.
• Future advancements in MIDD will further solidify its role, especially in cell and gene therapies.